| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pharmacogenetics | 39 | 2023 | 443 | 12.450 |
Why?
|
| Pharmacogenomic Testing | 14 | 2022 | 98 | 6.560 |
Why?
|
| Carcinoma, Transitional Cell | 21 | 2024 | 171 | 5.930 |
Why?
|
| Urologic Neoplasms | 17 | 2024 | 84 | 4.130 |
Why?
|
| Precision Medicine | 15 | 2023 | 410 | 4.040 |
Why?
|
| Urinary Bladder Neoplasms | 18 | 2024 | 401 | 3.190 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 7 | 2022 | 203 | 3.130 |
Why?
|
| Antineoplastic Agents | 23 | 2024 | 2415 | 2.230 |
Why?
|
| Cisplatin | 18 | 2024 | 618 | 2.220 |
Why?
|
| Pharmacogenomic Variants | 4 | 2021 | 42 | 2.220 |
Why?
|
| Decision Support Systems, Clinical | 5 | 2019 | 105 | 1.950 |
Why?
|
| Perioperative Care | 6 | 2022 | 170 | 1.840 |
Why?
|
| Antibodies, Monoclonal | 14 | 2024 | 1412 | 1.790 |
Why?
|
| Drug Prescriptions | 5 | 2021 | 144 | 1.590 |
Why?
|
| Immunoconjugates | 2 | 2022 | 113 | 1.540 |
Why?
|
| Neoplasms | 10 | 2022 | 3041 | 1.480 |
Why?
|
| Biomarkers, Tumor | 7 | 2022 | 1549 | 1.480 |
Why?
|
| Clinical Decision-Making | 5 | 2021 | 281 | 1.460 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2020 | 244 | 1.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 13 | 2024 | 969 | 1.400 |
Why?
|
| Patient Portals | 2 | 2020 | 17 | 1.400 |
Why?
|
| Humans | 118 | 2024 | 89356 | 1.340 |
Why?
|
| Decision Support Techniques | 2 | 2021 | 167 | 1.320 |
Why?
|
| Prescription Drugs | 2 | 2019 | 36 | 1.280 |
Why?
|
| Anesthesiology | 2 | 2022 | 162 | 1.250 |
Why?
|
| Genotype | 11 | 2023 | 1849 | 1.230 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2021 | 2401 | 1.210 |
Why?
|
| Capecitabine | 6 | 2024 | 98 | 1.180 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2021 | 601 | 1.090 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2020 | 260 | 1.080 |
Why?
|
| Aged, 80 and over | 27 | 2024 | 6811 | 1.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2020 | 533 | 1.010 |
Why?
|
| Genomics | 5 | 2022 | 762 | 1.000 |
Why?
|
| Cardiovascular Agents | 2 | 2015 | 54 | 0.970 |
Why?
|
| Middle Aged | 47 | 2024 | 25974 | 0.970 |
Why?
|
| Aged | 41 | 2024 | 19165 | 0.950 |
Why?
|
| Urothelium | 5 | 2023 | 71 | 0.930 |
Why?
|
| Prospective Studies | 12 | 2022 | 4289 | 0.930 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2016 | 890 | 0.910 |
Why?
|
| Male | 52 | 2024 | 42411 | 0.880 |
Why?
|
| Point-of-Care Systems | 3 | 2019 | 148 | 0.840 |
Why?
|
| Female | 51 | 2024 | 46202 | 0.820 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.810 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 198 | 0.790 |
Why?
|
| Germ-Line Mutation | 4 | 2020 | 344 | 0.790 |
Why?
|
| Kidney Neoplasms | 5 | 2021 | 638 | 0.790 |
Why?
|
| Pain Management | 2 | 2021 | 138 | 0.780 |
Why?
|
| Hepatic Veno-Occlusive Disease | 2 | 2012 | 19 | 0.770 |
Why?
|
| Busulfan | 2 | 2012 | 41 | 0.770 |
Why?
|
| Adult | 36 | 2023 | 26607 | 0.750 |
Why?
|
| Platinum | 5 | 2023 | 63 | 0.750 |
Why?
|
| Anesthetics | 1 | 2021 | 53 | 0.750 |
Why?
|
| B7-H1 Antigen | 9 | 2022 | 274 | 0.740 |
Why?
|
| Rheumatology | 1 | 2021 | 35 | 0.730 |
Why?
|
| Analgesics | 1 | 2021 | 119 | 0.720 |
Why?
|
| Anesthesia | 1 | 2022 | 170 | 0.690 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2021 | 437 | 0.670 |
Why?
|
| Drug Labeling | 2 | 2017 | 41 | 0.640 |
Why?
|
| Information Dissemination | 1 | 2019 | 114 | 0.630 |
Why?
|
| Medication Adherence | 1 | 2020 | 140 | 0.630 |
Why?
|
| Drug Therapy | 2 | 2018 | 70 | 0.620 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 711 | 0.620 |
Why?
|
| Pharmacology, Clinical | 1 | 2018 | 8 | 0.620 |
Why?
|
| Quinazolines | 2 | 2016 | 221 | 0.600 |
Why?
|
| Medical Order Entry Systems | 1 | 2017 | 25 | 0.580 |
Why?
|
| Germ Cells | 2 | 2022 | 130 | 0.570 |
Why?
|
| Follow-Up Studies | 11 | 2022 | 3666 | 0.560 |
Why?
|
| Analgesics, Opioid | 1 | 2021 | 444 | 0.560 |
Why?
|
| Patient Care | 1 | 2018 | 102 | 0.560 |
Why?
|
| Vidarabine | 3 | 2012 | 143 | 0.550 |
Why?
|
| Genome, Human | 3 | 2019 | 767 | 0.550 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2016 | 25 | 0.540 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 360 | 0.540 |
Why?
|
| Fluorouracil | 2 | 2023 | 561 | 0.540 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 20 | 0.530 |
Why?
|
| Benzamides | 3 | 2024 | 237 | 0.530 |
Why?
|
| Critical Care | 1 | 2019 | 382 | 0.530 |
Why?
|
| Physician's Role | 1 | 2017 | 177 | 0.510 |
Why?
|
| Clinical Medicine | 1 | 2015 | 34 | 0.500 |
Why?
|
| Cytochrome P-450 CYP2D6 | 3 | 2022 | 52 | 0.500 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2015 | 85 | 0.500 |
Why?
|
| Collagen Type I | 1 | 2015 | 72 | 0.500 |
Why?
|
| Physician-Patient Relations | 2 | 2019 | 625 | 0.500 |
Why?
|
| Snake Venoms | 2 | 2015 | 10 | 0.500 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2014 | 172 | 0.500 |
Why?
|
| Patient Selection | 3 | 2018 | 684 | 0.490 |
Why?
|
| Academic Medical Centers | 2 | 2015 | 385 | 0.490 |
Why?
|
| Quality of Life | 6 | 2024 | 1668 | 0.490 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2022 | 171 | 0.480 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 246 | 0.470 |
Why?
|
| Pyrroles | 2 | 2015 | 187 | 0.460 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2019 | 2340 | 0.460 |
Why?
|
| Transplantation Conditioning | 4 | 2014 | 374 | 0.450 |
Why?
|
| Inflammation | 1 | 2019 | 972 | 0.450 |
Why?
|
| Cardiology | 1 | 2015 | 115 | 0.450 |
Why?
|
| Program Development | 1 | 2014 | 123 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2024 | 2566 | 0.440 |
Why?
|
| Ambulatory Care | 2 | 2014 | 187 | 0.440 |
Why?
|
| Indoles | 2 | 2015 | 314 | 0.440 |
Why?
|
| Neovascularization, Pathologic | 1 | 2015 | 364 | 0.430 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2012 | 21 | 0.420 |
Why?
|
| Hematologic Neoplasms | 4 | 2016 | 343 | 0.420 |
Why?
|
| Nectins | 2 | 2022 | 9 | 0.420 |
Why?
|
| Pain | 4 | 2024 | 400 | 0.410 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 282 | 0.410 |
Why?
|
| Mutation | 6 | 2020 | 4143 | 0.410 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2024 | 192 | 0.410 |
Why?
|
| Cystectomy | 2 | 2024 | 110 | 0.400 |
Why?
|
| Peptides | 1 | 2015 | 648 | 0.390 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2016 | 605 | 0.390 |
Why?
|
| Pharmaceutical Preparations | 1 | 2012 | 92 | 0.380 |
Why?
|
| Kidney Failure, Chronic | 2 | 2016 | 414 | 0.370 |
Why?
|
| Treatment Outcome | 18 | 2024 | 8241 | 0.370 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 2018 | 0.370 |
Why?
|
| Cell Adhesion Molecules | 2 | 2022 | 167 | 0.370 |
Why?
|
| Prognosis | 12 | 2020 | 3783 | 0.370 |
Why?
|
| Patient Safety | 4 | 2023 | 218 | 0.370 |
Why?
|
| Deoxycytidine | 1 | 2012 | 238 | 0.360 |
Why?
|
| Antibodies, Neoplasm | 1 | 2010 | 84 | 0.360 |
Why?
|
| Drug Delivery Systems | 1 | 2012 | 179 | 0.360 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 1365 | 0.360 |
Why?
|
| Hemoglobinopathies | 1 | 2010 | 10 | 0.350 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2011 | 618 | 0.350 |
Why?
|
| Carcinoma | 3 | 2021 | 443 | 0.340 |
Why?
|
| Neoplasm Metastasis | 7 | 2024 | 1109 | 0.340 |
Why?
|
| Kidney Medulla | 1 | 2010 | 81 | 0.340 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 782 | 0.340 |
Why?
|
| BK Virus | 1 | 2009 | 23 | 0.340 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2019 | 1942 | 0.330 |
Why?
|
| Polyomavirus Infections | 1 | 2009 | 28 | 0.330 |
Why?
|
| Carboplatin | 6 | 2016 | 312 | 0.330 |
Why?
|
| Hematuria | 1 | 2009 | 50 | 0.330 |
Why?
|
| Tumor Virus Infections | 1 | 2009 | 81 | 0.330 |
Why?
|
| Pyrimidines | 3 | 2018 | 374 | 0.320 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 2 | 2024 | 121 | 0.320 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 3011 | 0.320 |
Why?
|
| Warfarin | 2 | 2019 | 104 | 0.320 |
Why?
|
| Genetic Testing | 4 | 2019 | 537 | 0.310 |
Why?
|
| Disease Susceptibility | 1 | 2009 | 200 | 0.310 |
Why?
|
| Genetic Variation | 3 | 2014 | 1374 | 0.310 |
Why?
|
| Anemia, Sickle Cell | 1 | 2010 | 144 | 0.290 |
Why?
|
| Risk Assessment | 3 | 2021 | 2303 | 0.290 |
Why?
|
| Surveys and Questionnaires | 3 | 2020 | 2624 | 0.290 |
Why?
|
| Models, Genetic | 1 | 2012 | 945 | 0.280 |
Why?
|
| Urinary Bladder | 3 | 2024 | 246 | 0.280 |
Why?
|
| Kidney Diseases | 1 | 2009 | 319 | 0.270 |
Why?
|
| Cohort Studies | 4 | 2019 | 2872 | 0.270 |
Why?
|
| Risk Factors | 5 | 2021 | 5499 | 0.270 |
Why?
|
| Genotyping Techniques | 2 | 2018 | 69 | 0.260 |
Why?
|
| Transplantation, Homologous | 7 | 2020 | 996 | 0.260 |
Why?
|
| Sirolimus | 1 | 2006 | 170 | 0.260 |
Why?
|
| Kidney | 1 | 2011 | 1147 | 0.250 |
Why?
|
| Neoplasm Invasiveness | 6 | 2024 | 576 | 0.250 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2019 | 838 | 0.250 |
Why?
|
| Neuroendocrine Tumors | 1 | 2006 | 118 | 0.240 |
Why?
|
| Tertiary Care Centers | 2 | 2016 | 106 | 0.230 |
Why?
|
| Phenylthiohydantoin | 1 | 2024 | 48 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 825 | 0.230 |
Why?
|
| Medical Oncology | 2 | 2022 | 383 | 0.230 |
Why?
|
| Nitriles | 1 | 2024 | 160 | 0.230 |
Why?
|
| Survival Analysis | 6 | 2023 | 1534 | 0.220 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2024 | 53 | 0.220 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 317 | 0.220 |
Why?
|
| Neutropenia | 1 | 2023 | 216 | 0.220 |
Why?
|
| Alemtuzumab | 3 | 2012 | 85 | 0.220 |
Why?
|
| Receptors, Glucocorticoid | 1 | 2024 | 131 | 0.210 |
Why?
|
| Adenine Nucleotides | 2 | 2014 | 63 | 0.210 |
Why?
|
| Arabinonucleosides | 2 | 2014 | 39 | 0.210 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 77 | 0.210 |
Why?
|
| Hospitalization | 2 | 2019 | 877 | 0.210 |
Why?
|
| Chicago | 5 | 2015 | 1427 | 0.210 |
Why?
|
| Thrombocytopenia | 1 | 2023 | 187 | 0.210 |
Why?
|
| Fenretinide | 1 | 2002 | 2 | 0.210 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.200 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.200 |
Why?
|
| Ceramides | 1 | 2002 | 35 | 0.200 |
Why?
|
| Hydralazine | 1 | 2022 | 19 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 1047 | 0.200 |
Why?
|
| Young Adult | 5 | 2019 | 6312 | 0.200 |
Why?
|
| Sulfonamides | 2 | 2016 | 318 | 0.200 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.200 |
Why?
|
| Lymphocytes | 3 | 2010 | 471 | 0.190 |
Why?
|
| Muscles | 1 | 2021 | 193 | 0.180 |
Why?
|
| Ferredoxin-NADP Reductase | 1 | 2020 | 15 | 0.180 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2020 | 27 | 0.180 |
Why?
|
| Genome-Wide Association Study | 7 | 2012 | 1671 | 0.170 |
Why?
|
| Pyrazines | 1 | 2020 | 94 | 0.170 |
Why?
|
| Research | 2 | 2019 | 252 | 0.170 |
Why?
|
| Disease-Free Survival | 6 | 2021 | 1214 | 0.170 |
Why?
|
| Inpatients | 1 | 2022 | 310 | 0.170 |
Why?
|
| Clinical Trials as Topic | 2 | 2016 | 1150 | 0.170 |
Why?
|
| Drug Recalls | 1 | 2019 | 13 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.170 |
Why?
|
| Codeine | 1 | 2019 | 12 | 0.170 |
Why?
|
| CREB-Binding Protein | 1 | 2018 | 16 | 0.160 |
Why?
|
| Phenotype | 3 | 2019 | 2440 | 0.160 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2018 | 14 | 0.160 |
Why?
|
| Pilot Projects | 2 | 2019 | 871 | 0.160 |
Why?
|
| Survival Rate | 3 | 2018 | 1901 | 0.160 |
Why?
|
| Predictive Value of Tests | 2 | 2021 | 1723 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2014 | 312 | 0.160 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 433 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2021 | 1265 | 0.160 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 463 | 0.160 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 4 | 2021 | 58 | 0.160 |
Why?
|
| Tumor Burden | 1 | 2019 | 308 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2019 | 307 | 0.150 |
Why?
|
| Infusions, Intravenous | 3 | 2017 | 435 | 0.150 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2002 | 395 | 0.150 |
Why?
|
| United States | 5 | 2017 | 6989 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2021 | 288 | 0.150 |
Why?
|
| Guidelines as Topic | 1 | 2019 | 160 | 0.150 |
Why?
|
| Abdominal Neoplasms | 1 | 2017 | 39 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2018 | 131 | 0.140 |
Why?
|
| Standard of Care | 1 | 2017 | 65 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 252 | 0.140 |
Why?
|
| Health Personnel | 1 | 2019 | 215 | 0.140 |
Why?
|
| Tissue Donors | 1 | 2020 | 494 | 0.140 |
Why?
|
| Disease Management | 1 | 2019 | 329 | 0.140 |
Why?
|
| Organoplatinum Compounds | 2 | 2019 | 97 | 0.140 |
Why?
|
| Drug Therapy, Computer-Assisted | 1 | 2016 | 8 | 0.140 |
Why?
|
| Hospital Mortality | 1 | 2019 | 387 | 0.140 |
Why?
|
| User-Computer Interface | 1 | 2017 | 187 | 0.140 |
Why?
|
| Social Perception | 1 | 2017 | 95 | 0.130 |
Why?
|
| Safety | 1 | 2017 | 149 | 0.130 |
Why?
|
| Anticoagulants | 1 | 2019 | 427 | 0.130 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 309 | 0.130 |
Why?
|
| Benzodioxoles | 1 | 2015 | 16 | 0.130 |
Why?
|
| Attitude to Health | 1 | 2017 | 222 | 0.130 |
Why?
|
| Immunotherapy | 2 | 2020 | 682 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2020 | 1862 | 0.130 |
Why?
|
| Universities | 2 | 2013 | 148 | 0.130 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2015 | 56 | 0.130 |
Why?
|
| Transcription Factor RelA | 1 | 2015 | 49 | 0.130 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 51 | 0.130 |
Why?
|
| G(M2) Ganglioside | 1 | 2015 | 3 | 0.130 |
Why?
|
| Tay-Sachs Disease | 1 | 2015 | 6 | 0.120 |
Why?
|
| Communication | 1 | 2019 | 460 | 0.120 |
Why?
|
| Forecasting | 1 | 2016 | 306 | 0.120 |
Why?
|
| Adolescent | 7 | 2023 | 9263 | 0.120 |
Why?
|
| Response Elements | 1 | 2015 | 65 | 0.120 |
Why?
|
| Tunica Intima | 1 | 2015 | 60 | 0.120 |
Why?
|
| Area Under Curve | 2 | 2014 | 337 | 0.120 |
Why?
|
| Fatal Outcome | 1 | 2015 | 299 | 0.120 |
Why?
|
| Ureter | 1 | 2016 | 93 | 0.120 |
Why?
|
| Epilepsies, Myoclonic | 1 | 2015 | 18 | 0.120 |
Why?
|
| Maximum Tolerated Dose | 2 | 2017 | 272 | 0.120 |
Why?
|
| Nomograms | 1 | 2014 | 29 | 0.120 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 645 | 0.120 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 299 | 0.120 |
Why?
|
| Kidney Transplantation | 2 | 2016 | 850 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 595 | 0.110 |
Why?
|
| Exome | 1 | 2014 | 127 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2017 | 347 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2017 | 758 | 0.110 |
Why?
|
| Genetic Markers | 1 | 2014 | 478 | 0.110 |
Why?
|
| Radiography | 1 | 2015 | 809 | 0.110 |
Why?
|
| Total Quality Management | 1 | 2013 | 33 | 0.110 |
Why?
|
| Software | 1 | 2017 | 665 | 0.110 |
Why?
|
| Receptors, Cell Surface | 1 | 2014 | 289 | 0.110 |
Why?
|
| Muscle Neoplasms | 1 | 2013 | 18 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2015 | 433 | 0.110 |
Why?
|
| Endonucleases | 1 | 2012 | 23 | 0.110 |
Why?
|
| Workflow | 1 | 2013 | 80 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 2012 | 9 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 1 | 2016 | 377 | 0.110 |
Why?
|
| Genetics, Medical | 1 | 2013 | 52 | 0.100 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 435 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2016 | 856 | 0.100 |
Why?
|
| DNA Repair | 1 | 2014 | 362 | 0.100 |
Why?
|
| Lymphocyte Depletion | 1 | 2012 | 98 | 0.100 |
Why?
|
| Models, Statistical | 1 | 2016 | 576 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2022 | 481 | 0.100 |
Why?
|
| Biopsy | 2 | 2016 | 1184 | 0.100 |
Why?
|
| Biomedical Research | 2 | 2013 | 398 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2016 | 836 | 0.100 |
Why?
|
| Disease Progression | 3 | 2016 | 1489 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2015 | 257 | 0.100 |
Why?
|
| Combined Modality Therapy | 3 | 2024 | 1719 | 0.100 |
Why?
|
| Time Factors | 3 | 2016 | 5338 | 0.100 |
Why?
|
| Fibroblasts | 1 | 2015 | 755 | 0.100 |
Why?
|
| T-Lymphocytes | 2 | 2022 | 1224 | 0.100 |
Why?
|
| Graft vs Host Disease | 2 | 2012 | 360 | 0.100 |
Why?
|
| Melphalan | 1 | 2011 | 98 | 0.100 |
Why?
|
| Decision Making | 1 | 2017 | 667 | 0.100 |
Why?
|
| HLA Antigens | 1 | 2012 | 227 | 0.090 |
Why?
|
| Population Groups | 1 | 2010 | 41 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 120 | 0.090 |
Why?
|
| Liver | 2 | 2014 | 1208 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 188 | 0.090 |
Why?
|
| Chromosomes, Human, X | 1 | 2011 | 55 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2012 | 216 | 0.090 |
Why?
|
| Graft Rejection | 2 | 2016 | 1070 | 0.090 |
Why?
|
| Postoperative Complications | 2 | 2016 | 2284 | 0.090 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2010 | 64 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2010 | 203 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2010 | 155 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 414 | 0.090 |
Why?
|
| Vinca Alkaloids | 1 | 2009 | 3 | 0.090 |
Why?
|
| Cell Line | 5 | 2011 | 2496 | 0.080 |
Why?
|
| Anthracyclines | 1 | 2009 | 38 | 0.080 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 487 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2010 | 519 | 0.080 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2009 | 138 | 0.080 |
Why?
|
| DNA | 1 | 2014 | 1308 | 0.080 |
Why?
|
| Haplotypes | 1 | 2010 | 637 | 0.080 |
Why?
|
| Creatinine | 1 | 2009 | 293 | 0.080 |
Why?
|
| Cell Proliferation | 2 | 2010 | 1652 | 0.070 |
Why?
|
| Genetics, Population | 1 | 2010 | 406 | 0.070 |
Why?
|
| Fatigue | 2 | 2022 | 179 | 0.070 |
Why?
|
| DNA-Binding Proteins | 1 | 2012 | 1242 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 742 | 0.070 |
Why?
|
| Incidence | 1 | 2010 | 1595 | 0.070 |
Why?
|
| Neurons | 1 | 2015 | 1583 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 975 | 0.060 |
Why?
|
| Drug Administration Schedule | 2 | 2017 | 895 | 0.060 |
Why?
|
| Kidney Function Tests | 2 | 2016 | 114 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 764 | 0.060 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2024 | 22 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3448 | 0.060 |
Why?
|
| Indazoles | 2 | 2016 | 67 | 0.060 |
Why?
|
| Models, Biological | 1 | 2011 | 1765 | 0.060 |
Why?
|
| Receptors, Androgen | 1 | 2024 | 123 | 0.060 |
Why?
|
| Head and Neck Neoplasms | 1 | 2011 | 1063 | 0.060 |
Why?
|
| Hyperparathyroidism | 1 | 2003 | 67 | 0.060 |
Why?
|
| Dihydrouracil Dehydrogenase (NADP) | 1 | 2023 | 29 | 0.050 |
Why?
|
| Parathyroidectomy | 1 | 2003 | 77 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2558 | 0.050 |
Why?
|
| Pharmacists | 1 | 2022 | 33 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2018 | 860 | 0.050 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 275 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2014 | 156 | 0.050 |
Why?
|
| Adrenal Insufficiency | 1 | 2022 | 23 | 0.050 |
Why?
|
| Sphingolipids | 1 | 2002 | 20 | 0.050 |
Why?
|
| Alleles | 2 | 2017 | 1135 | 0.050 |
Why?
|
| Vaccines, Synthetic | 1 | 2022 | 55 | 0.050 |
Why?
|
| Morpholines | 1 | 2002 | 69 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2758 | 0.050 |
Why?
|
| Antibody Formation | 1 | 2022 | 171 | 0.050 |
Why?
|
| Age Factors | 2 | 2020 | 1870 | 0.050 |
Why?
|
| Drug Synergism | 1 | 2002 | 306 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2022 | 178 | 0.050 |
Why?
|
| DNA Damage | 1 | 2023 | 371 | 0.050 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2021 | 53 | 0.050 |
Why?
|
| Gene Fusion | 1 | 2021 | 39 | 0.050 |
Why?
|
| Bone Marrow Transplantation | 1 | 2001 | 283 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2001 | 169 | 0.050 |
Why?
|
| Risk | 2 | 2012 | 657 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 309 | 0.050 |
Why?
|
| Hodgkin Disease | 1 | 2001 | 181 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 1057 | 0.040 |
Why?
|
| Prostatic Neoplasms | 1 | 2011 | 1769 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 274 | 0.040 |
Why?
|
| Cell Survival | 1 | 2002 | 983 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2021 | 307 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2023 | 1719 | 0.040 |
Why?
|
| Allografts | 1 | 2020 | 181 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2020 | 166 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1310 | 0.040 |
Why?
|
| Blood Platelets | 1 | 2019 | 150 | 0.040 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2018 | 92 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 108 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2021 | 665 | 0.040 |
Why?
|
| Internationality | 1 | 2017 | 69 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 150 | 0.040 |
Why?
|
| BCG Vaccine | 1 | 2017 | 35 | 0.040 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 338 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 740 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 529 | 0.030 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2017 | 125 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2016 | 78 | 0.030 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2016 | 65 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2018 | 394 | 0.030 |
Why?
|
| Cholesterol, Dietary | 1 | 2015 | 27 | 0.030 |
Why?
|
| Transplants | 1 | 2016 | 41 | 0.030 |
Why?
|
| E-Selectin | 1 | 2015 | 30 | 0.030 |
Why?
|
| Carotid Artery Injuries | 1 | 2015 | 22 | 0.030 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2015 | 38 | 0.030 |
Why?
|
| Glycoside Hydrolase Inhibitors | 1 | 2015 | 1 | 0.030 |
Why?
|
| 1-Deoxynojirimycin | 1 | 2015 | 3 | 0.030 |
Why?
|
| Receptors, LDL | 1 | 2015 | 55 | 0.030 |
Why?
|
| RNA Polymerase II | 1 | 2015 | 57 | 0.030 |
Why?
|
| Netrin Receptors | 1 | 2014 | 7 | 0.030 |
Why?
|
| Protein Interaction Mapping | 1 | 2015 | 82 | 0.030 |
Why?
|
| Hyperglycemia | 1 | 2016 | 172 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2015 | 76 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 43 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 682 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2016 | 137 | 0.030 |
Why?
|
| Microsomes, Liver | 1 | 2014 | 49 | 0.030 |
Why?
|
| Transduction, Genetic | 1 | 2015 | 160 | 0.030 |
Why?
|
| Transgenes | 1 | 2015 | 185 | 0.030 |
Why?
|
| Recurrence | 2 | 2011 | 1144 | 0.030 |
Why?
|
| Plasmids | 1 | 2015 | 291 | 0.030 |
Why?
|
| Reference Standards | 1 | 2014 | 144 | 0.030 |
Why?
|
| Ireland | 1 | 2013 | 9 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 371 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2017 | 575 | 0.030 |
Why?
|
| Nephrectomy | 1 | 2016 | 295 | 0.030 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 172 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2015 | 446 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 155 | 0.030 |
Why?
|
| Transplantation Chimera | 1 | 2012 | 81 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2015 | 460 | 0.030 |
Why?
|
| United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
| Graft Survival | 1 | 2016 | 900 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2018 | 9057 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 956 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2016 | 1799 | 0.020 |
Why?
|
| Students | 1 | 2013 | 170 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2015 | 511 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 72 | 0.020 |
Why?
|
| Transplantation, Autologous | 2 | 2003 | 344 | 0.020 |
Why?
|
| Contrast Media | 1 | 2016 | 1091 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 543 | 0.020 |
Why?
|
| Action Potentials | 1 | 2015 | 600 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1146 | 0.020 |
Why?
|
| Genes, X-Linked | 1 | 2011 | 38 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 182 | 0.020 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1157 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 851 | 0.020 |
Why?
|
| Mice, Knockout | 1 | 2015 | 2001 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 231 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2015 | 2884 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2011 | 261 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2010 | 119 | 0.020 |
Why?
|
| Quality Improvement | 1 | 2013 | 451 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2010 | 316 | 0.020 |
Why?
|
| Laparoscopy | 1 | 2016 | 773 | 0.020 |
Why?
|
| Registries | 1 | 2013 | 784 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1840 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2015 | 1525 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 3218 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 540 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2016 | 1176 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2015 | 1653 | 0.020 |
Why?
|
| Child | 2 | 2012 | 7174 | 0.020 |
Why?
|
| Physicians | 1 | 2013 | 690 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 1431 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2011 | 793 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 1767 | 0.010 |
Why?
|
| Baltimore | 1 | 2001 | 40 | 0.010 |
Why?
|
| Mice | 1 | 2015 | 11761 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2001 | 1072 | 0.010 |
Why?
|
| Animals | 1 | 2015 | 27369 | 0.010 |
Why?
|